Editor, Intravitreal anti-vascular endothelial growth factor (anti-VEGF) injections to the retina have become the standard of care for wet age-related macular degeneration (wAMD). Despite the overall success of intravitreal injections with agents such as ranibizumab or aflibercept 2 mg, many patients require frequent, long-term treatment with limited possibility for interval extension.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Idan
Contact Idan, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack